Following Merger with Idera Pharmaceuticals, Aceragen Cuts Costs ... - BioBuzz
ACGNDelisted Stock | 0.75 0.23 23.47% |
About 61% of Aceragen's investor base is looking to short. The analysis of current outlook of investing in Aceragen suggests that many traders are alarmed regarding Aceragen's prospects. Aceragen's investing sentiment overview a quick insight into current market opportunities from investing in Aceragen. Many technical investors use Aceragen stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Aceragen |
Following Merger with Idera Pharmaceuticals, Aceragen Cuts Costs ... BioBuzz
Read at news.google.com
Aceragen Fundamental Analysis
We analyze Aceragen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aceragen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aceragen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Aceragen is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Aceragen Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aceragen stock to make a market-neutral strategy. Peer analysis of Aceragen could also be used in its relative valuation, which is a method of valuing Aceragen by comparing valuation metrics with similar companies.
Peers
Aceragen Related Equities
SNTI | Senti Biosciences | 2.01 | ||||
ACXP | Acurx Pharmaceuticals | 1.14 | ||||
ADXN | Addex Therapeutics | 0.76 | ||||
SABS | SAB Biotherapeutics | 0.52 | ||||
PCSA | Processa Pharmaceuticals | 0.79 | ||||
COCP | Cocrystal Pharma | 1.06 | ||||
ATXI | Avenue Therapeutics | 2.11 | ||||
TPST | Tempest Therapeutics | 2.35 | ||||
AKTX | Akari Therapeutics | 3.06 | ||||
ARMP | Armata Pharmaceuticals | 4.55 | ||||
SNGX | Soligenix | 4.61 | ||||
BPTH | Bio Path | 5.41 | ||||
IBIO | Ibio | 5.64 | ||||
ACRV | Acrivon Therapeutics, | 5.65 | ||||
QNRX | Quoin Pharmaceuticals | 5.84 | ||||
RNXT | RenovoRx | 6.38 | ||||
ANEB | Anebulo Pharmaceuticals | 11.46 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Aceragen Stock
If you are still planning to invest in Aceragen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aceragen's history and understand the potential risks before investing.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |